<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.cerebrospinalfluidresearch.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Cerebrospinal Fluid Research - Latest Articles</title>
        <link>http://www.cerebrospinalfluidresearch.com</link>
        <description>The latest research articles published by Cerebrospinal Fluid Research</description>
        <dc:date>2010-07-30T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.cerebrospinalfluidresearch.com/content/7/1/10" />
                                <rdf:li rdf:resource="http://www.cerebrospinalfluidresearch.com/content/7/1/9" />
                                <rdf:li rdf:resource="http://www.cerebrospinalfluidresearch.com/content/7/1/8" />
                                <rdf:li rdf:resource="http://www.cerebrospinalfluidresearch.com/content/7/1/7" />
                                <rdf:li rdf:resource="http://www.cerebrospinalfluidresearch.com/content/7/1/6" />
                                <rdf:li rdf:resource="http://www.cerebrospinalfluidresearch.com/content/7/1/5" />
                                <rdf:li rdf:resource="http://www.cerebrospinalfluidresearch.com/content/7/1/4" />
                                <rdf:li rdf:resource="http://www.cerebrospinalfluidresearch.com/content/7/1/3" />
                                <rdf:li rdf:resource="http://www.cerebrospinalfluidresearch.com/content/7/1/2" />
                                <rdf:li rdf:resource="http://www.cerebrospinalfluidresearch.com/content/7/1/1" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.cerebrospinalfluidresearch.com/content/7/1/10">
        <title>Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid</title>
        <description>Background:
Alzheimer&apos;s disease (AD) and cerebrovascular disease (CVD) including chronic small vessel disease of the brain (SVD) are the most frequent causes of dementia. AD is associated with metabolism of amyloid precursor protein (APP) and low levels of amyloid-beta peptide (Abeta) X-42 in the cerebrospinal fluid (CSF). CVD and SVD are established risk factors for AD, brain white matter lesions (WML) are established surrogate markers for SVD and are also associated with reduced CSF AbetaX-42.A cohort survey was performed to examine whether SVD or acute CVD affects APP metabolism and to explore a potential association between WML and APP metabolism in two groups; cognitively impaired patients, subjective and mild (SCI and MCI) and stroke patients. Through measurements of CSF APP metabolite levels in patients with a wide range of WML volumes, this study aimed to determine how SVD influences APP metabolism.
Methods:
Sixty-three patients were included: 37 with subjective cognitive impairment (SCI) or mild cognitive impairment (MCI) without stroke, and 26 after acute stroke. Chronic and acute WML volume and infarct volume were determined by magnetic resonance imaging (MRI) post-scan processing, and CSF levels of alpha- and beta-cleaved soluble APP (sAPP-alpha and sAPP-beta, AbetaX-38, AbetaX-40 and AbetaX-42) were determined. The Mann-Whitney test was used to compare the patient groups. Chronic and acute WML volumes, infarct volume, age, and sex were used as predictors for CSF biomarker levels in linear regression analysis.
Results:
CSF levels of sAPP-alpha and sAPP-beta were strongly correlated (r=0.95, p&lt;0.001) and lower levels of these biomarkers were found in the stroke group than in the SCI/MCI group; median sAPP-alpha 499.5 vs. 698.0 ng/mL (p&lt;0.001), sAPP-beta 258.0 vs. 329.0 ng/mL (p&lt;0.005). CSF levels of sAPP-alpha, sAPP-beta, AbetaX-38, AbetaX-40 and AbetaX-42 were inversely correlated with chronic WML volume (p[less than or equal to]0.005; p[less than or equal to]0.01; p[less than or equal to]0.01; p[less than or equal to]0.05; p[less than or equal to]0.05 respectively), but not with acute WML or infarct volumes.
Conclusions:
Lower CSF levels of sAPP-alpha and sAPP-beta in the stroke group than in the SCI/MCI group and an inverse correlation with chronic WML indicate that ischemia lowers the levels of CSF sAPP metabolites and suggests that APP axonal transport or metabolism may be affected in SVD of the brain.</description>
        <link>http://www.cerebrospinalfluidresearch.com/content/7/1/10</link>
                <dc:creator>Per Selnes</dc:creator>
                <dc:creator>Kaj Blennow</dc:creator>
                <dc:creator>Henrik Zetterberg</dc:creator>
                <dc:creator>Ramune Grambaite</dc:creator>
                <dc:creator>Lars Rosengren</dc:creator>
                <dc:creator>Lisbeth Johnsen</dc:creator>
                <dc:creator>Vidar Stenset</dc:creator>
                <dc:creator>Tormod Fladby</dc:creator>
                <dc:source>Cerebrospinal Fluid Research 2010, 7:10</dc:source>
        <dc:date>2010-07-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-8454-7-10</dc:identifier>
        <prism:publicationName>Cerebrospinal Fluid Research</prism:publicationName>
        <prism:issn>1743-8454</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2010-07-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cerebrospinalfluidresearch.com/content/7/1/9">
        <title>The Function and Structure of the CSF Outflow System</title>
        <description>This review traces the development of our understanding of the anatomy and physiological properties of the two systems responsible for the drainage of cerebrospinal fluid (CSF) into the systemic circulation. The roles of the cranial and spinal arachnoid villi (AV) and the lymphatic outflow systems are evaluated as to the dominance of one over the other in various species and degree of animal maturation. The functional capabilities of the total CSF drainage system are presented, with evidence that the duality of the system is supported by the changes in fluid outflow dynamics in human and sub-human primates in hydrocephalus. The review also reconciles the relative importance and alterations of each of the outflow systems in a variety of clinical pathological conditions.</description>
        <link>http://www.cerebrospinalfluidresearch.com/content/7/1/9</link>
                <dc:creator>Michael Pollay</dc:creator>
                <dc:source>Cerebrospinal Fluid Research 2010, 7:9</dc:source>
        <dc:date>2010-06-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-8454-7-9</dc:identifier>
        <prism:publicationName>Cerebrospinal Fluid Research</prism:publicationName>
        <prism:issn>1743-8454</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2010-06-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cerebrospinalfluidresearch.com/content/7/1/8">
        <title>Arachnoid cysts do not contain cerebrospinal fluid: A comparative chemical analysis of arachnoid cyst fluid and cerebrospinal fluid in adults </title>
        <description>Background:
Arachnoid cyst (AC) fluid has not previously been compared with cerebrospinal fluid (CSF) from the same patient. ACs are commonly referred to as containing &quot;CSF-like fluid&quot;. The objective of this study was to characterize AC fluid by clinical chemistry and to compare AC fluid to CSF drawn from the same patient. Such comparative analysis can shed further light on the mechanisms for filling and sustaining of ACs.
Methods:
Cyst fluid from 15 adult patients with unilateral temporal AC (9 female, 6 male, age 22-77y) was compared with CSF from the same patients by clinical chemical analysis.
Results:
AC fluid and CSF had the same osmolarity. There were no significant differences in the concentrations of sodium, potassium, chloride, calcium, magnesium or glucose. We found significant elevated concentration of phosphate in AC fluid (0.39 versus 0.35 mmol/L in CSF; p = 0.02), and significantly reduced concentrations of total protein (0.30 versus 0.41 g/L; p = 0.004), of ferritin (7.8 versus 25.5 ug/L; p = 0.001) and of lactate dehydrogenase (17.9 versus 35.6 U/L; p = 0.002) in AC fluid relative to CSF.
Conclusions:
AC fluid is not identical to CSF. The differential composition of AC fluid relative to CSF supports secretion or active transport as the mechanism underlying cyst filling. Oncotic pressure gradients or slit-valves as mechanisms for generating fluid in temporal ACs are not supported by these results.</description>
        <link>http://www.cerebrospinalfluidresearch.com/content/7/1/8</link>
                <dc:creator>Magnus Berle</dc:creator>
                <dc:creator>Knut Wester</dc:creator>
                <dc:creator>Rune Ulvik</dc:creator>
                <dc:creator>Ann Kroksveen</dc:creator>
                <dc:creator>Oystein Haaland</dc:creator>
                <dc:creator>Mahmood Amiry-Moghaddam</dc:creator>
                <dc:creator>Frode Berven</dc:creator>
                <dc:creator>Christian Helland</dc:creator>
                <dc:source>Cerebrospinal Fluid Research 2010, 7:8</dc:source>
        <dc:date>2010-06-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-8454-7-8</dc:identifier>
        <prism:publicationName>Cerebrospinal Fluid Research</prism:publicationName>
        <prism:issn>1743-8454</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2010-06-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cerebrospinalfluidresearch.com/content/7/1/7">
        <title>Minocycline inhibits glial proliferation in the H-Tx rat model of congenital hydrocephalus</title>
        <description>Background:
Reactive astrocytosis and microgliosis are important features of the pathophysiology of hydrocephalus, and persistent glial &quot;scars&quot; that form could exacerbate neuroinflammation, impair cerebral perfusion, impede neuronal regeneration, and alter biomechanical properties. The purpose of this study was to determine the efficacy of minocycline, an antibiotic known for its anti-inflammatory properties, to reduce gliosis in the H-Tx rat model of congenital hydrocephalus.
Methods:
Minocycline (45 mg/kg/day i.p. in 5% sucrose at a concentration of 5-10 mg/ml) was administered to hydrocephalic H-Tx rats from postnatal day 15 to day 21, when ventriculomegaly had reached moderate to severe stages. Treated animals were compared to age-matched non-hydrocephalic and untreated hydrocephalic littermates. The cerebral cortex (both gray matter laminae and white matter) was processed for immunohistochemistry (glial fibrillary acidic protein, GFAP, for astrocytes and ionized calcium binding adaptor molecule, Iba-1, for microglia) and analyzed by qualitative and quantitative light microscopy.
Results:
The mean number of GFAP-immunoreactive astrocytes was significantly higher in untreated hydrocephalic animals compared to both types of controls (p &lt; 0.001). Minocycline treatment of hydrocephalic animals reduced the number of GFAP immunoreactive cells significantly (p &lt; 0.001). Likewise, the mean number of Iba-1 immunoreactive microglia was significantly higher in untreated hydrocephalic animals compared to both types of controls (p &lt; 0.001). Furthermore, no differences in the numbers of GFAP-positive astrocytes or Iba-1-positive microglia were noted between control animals receiving no minocycline and control animals receiving minocycline, suggesting that minocycline does not produce an effect under non-injury conditions. Additionally, in six out of nine regions sampled, hydrocephalic animals that received minocycline injections had significantly thicker cortices when compared to their untreated hydrocephalic littermates.
Conclusions:
Overall, these data suggest that minocycline treatment is effective in reducing the gliosis that accompanies hydrocephalus, and thus may provide an added benefit when used as a supplement to ventricular shunting.</description>
        <link>http://www.cerebrospinalfluidresearch.com/content/7/1/7</link>
                <dc:creator>James McAllister</dc:creator>
                <dc:creator>Janet Miller</dc:creator>
                <dc:source>Cerebrospinal Fluid Research 2010, 7:7</dc:source>
        <dc:date>2010-05-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-8454-7-7</dc:identifier>
        <prism:publicationName>Cerebrospinal Fluid Research</prism:publicationName>
        <prism:issn>1743-8454</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2010-05-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cerebrospinalfluidresearch.com/content/7/1/6">
        <title>Microarray-based gene expression profiling and DNA copy number variation analysis of temporal fossa arachnoid cysts</title>
        <description>Background:
Intracranial arachnoid cysts (AC) are membranous sacs filled with CSF-like fluid that are commonly found in the temporal fossa. The majority of ACs are congenital. Typical symptoms are headache, dizziness, and dyscognition. Little is known about genes that contribute to the formation of the cyst membranes.
Methods:
In order to identify differences in gene expression between normal arachnoid membrane (AM) and cyst membrane, we have performed a high-resolution mRNA microarray analysis. In addition we have screened DNA from AC samples for chromosomal duplications or deletions using DNA microarray-based copy number variation analysis.
Results:
The transcriptome consisting of 33096 gene probes showed a near-complete similarity in expression between AC and AM samples. Only nine genes differed in expression between the two tissues: ASGR1, DPEP2, SOX9, SHROOM3, A2BP1, ATP10D, TRIML1, NMU were down regulated, whereas BEND5 was up regulated in the AC samples. Three of the AC samples had unreported human DNA copy number variations, all DNA gains.
Conclusions:
Extending results of previous anatomical studies, the present study has identified a small subset of differentially expressed genes and DNA alterations in arachnoid cysts compared to normal arachnoid membrane.</description>
        <link>http://www.cerebrospinalfluidresearch.com/content/7/1/6</link>
                <dc:creator>Mads Aarhus</dc:creator>
                <dc:creator>Christian Helland</dc:creator>
                <dc:creator>Morten Lund-Johansen</dc:creator>
                <dc:creator>Knut Wester</dc:creator>
                <dc:creator>Per Knappskog</dc:creator>
                <dc:source>Cerebrospinal Fluid Research 2010, 7:6</dc:source>
        <dc:date>2010-02-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-8454-7-6</dc:identifier>
        <prism:publicationName>Cerebrospinal Fluid Research</prism:publicationName>
        <prism:issn>1743-8454</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2010-02-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cerebrospinalfluidresearch.com/content/7/1/5">
        <title>Cerebrospinal fluid pulse pressure amplitude during lumbar infusion in idiopathic normal pressure hydrocephalus can predict response to shunting</title>
        <description>Background:
We have previously seen that idiopathic normal pressure hydrocephalus (iNPH) patients having elevated intracranial pressure (ICP) pulse amplitude consistently respond to shunt surgery. In this study we explored how the cerebrospinal fluid pressure (CSFP) pulse amplitude determined during lumbar infusion testing, correlates with ICP pulse amplitude determined during over-night ICP monitoring and with response to shunt surgery. Our goal was to establish a more reliable screening procedure for selecting iNPH patients for shunt surgery using lumbar intrathecal infusion.
Methods:
The study population consisted of all iNPH patients undergoing both diagnostic lumbar infusion testing and continuous over-night ICP monitoring during the period 2002-2007. The severity of iNPH was assessed using our NPH grading scale before surgery and 12 months after shunting. The CSFP pulse was characterized from the amplitude of single pressure waves.
Results:
Totally 62 iNPH patients were included, 45 of them underwent shunt surgery, in whom 78% were shunt responders. Among the 45 shunted patients, resistance to CSF outflow (Rout) was elevated (&#8805; 12 mmHg/ml/min) in 44. The ICP pulse amplitude recorded over-night was elevated (i.e. mean ICP wave amplitude &#8805; 4 mmHg) in 68% of patients; 92% of these were shunt responders. In those with elevated overnight ICP pulse amplitude, we found also elevated CSFP pulse amplitude recorded during lumbar infusion testing, both during the opening phase following lumbar puncture and during a standardized period of lumbar infusion (15 ml Ringer over 10 min). The clinical response to shunting after 1 year strongly associated with the over-night ICP pulse amplitude, and also with the pulsatile CSFP during the period of lumbar infusion. Elevated CSFP pulse amplitude during lumbar infusion thus predicted shunt response with sensitivity of 88 and specificity of 60 (positive and negative predictive values of 89 and 60, respectively).
Conclusions:
In iNPH patients, shunt response can be anticipated in 9/10 patients with elevated overnight ICP pulse amplitude, while in only 1/10 with low ICP pulse amplitude. Additionally, the CSFP pulse amplitude during lumbar infusion testing was elevated in patients with elevated over-night ICP pulse amplitude. In particular, measurement of CSFP pulse amplitude during a standardized infusion of 15 ml Ringer over 10 min was useful in predicting response to shunt surgery and can be used as a screening procedure for selection of iNPH patients for shunting.</description>
        <link>http://www.cerebrospinalfluidresearch.com/content/7/1/5</link>
                <dc:creator>Per Eide</dc:creator>
                <dc:creator>Are Brean</dc:creator>
                <dc:source>Cerebrospinal Fluid Research 2010, 7:5</dc:source>
        <dc:date>2010-02-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-8454-7-5</dc:identifier>
        <prism:publicationName>Cerebrospinal Fluid Research</prism:publicationName>
        <prism:issn>1743-8454</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2010-02-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cerebrospinalfluidresearch.com/content/7/1/4">
        <title>Elevated CSF outflow resistance associated with impaired lymphatic CSF absorption in a rat model of kaolin-induced communicating hydrocephalus</title>
        <description>Background:
We recently reported a lymphatic cerebrospinal fluid (CSF) absorption deficit in a kaolin model of communicating hydrocephalus in rats with ventricular expansion correlating negatively with the magnitude of the impediment to lymphatic function. However, it is possible that CSF drainage was not significantly altered if absorption at other sites compensated for the lymphatic defect. The purpose of this study was to investigate the impact of the lymphatic absorption deficit on global CSF absorption (CSF outflow resistance).
Methods:
Kaolin was injected into the basal cisterns of Sprague Dawley rats. The development of hydrocephalus was assessed using magnetic resonance imaging (MRI). In one group of animals at about 3 weeks after injection, the movement of intraventricularly injected iodinated human serum albumin (125I-HSA) into the olfactory turbinates provided an estimate of CSF transport through the cribriform plate into nasal lymphatics (n = 18). Control animals received saline in place of kaolin (n = 10). In a second group at about 3.5 weeks after kaolin injection, intraventricular pressure was measured continuously during infusion of saline into the spinal subarachnoid space at various flow rates (n = 9). CSF outflow resistance was calculated as the slope of the steady-state pressure versus flow rate. Control animals for this group either received no injections (intact: n = 11) or received saline in place of kaolin (n = 8).
Results:
Compared to saline injected controls, lateral ventricular volume in the kaolin group was significantly greater (0.087 &#177; 0.013 ml, n = 27 versus 0.015 &#177; 0.001 ml, n = 17) and lymphatic function was significantly less (2.14 &#177; 0.72% injected/g, n = 18 versus 6.38 &#177; 0.60% injected/g, n = 10). Additionally, the CSF outflow resistance was significantly greater in the kaolin group (0.46 &#177; 0.04 cm H2O.&#956;L-1.min, n = 9) than in saline injected (0.28 &#177; 0.03 cm H2O.&#956;L-1.min, n = 8) or intact animals (0.18 &#177; 0.03 cm H2O.&#956;L-1.min, n = 11). There was a significant positive correlation between CSF outflow resistance and ventricular volume.
Conclusions:
The data suggest that the impediment to lymphatic CSF absorption in a kaolin-induced model of communicating hydrocephalus has a significant impact on global CSF absorption. A lymphatic CSF absorption deficit would appear to play some role (either direct or indirect) in the pathogenesis of ventriculomegaly.</description>
        <link>http://www.cerebrospinalfluidresearch.com/content/7/1/4</link>
                <dc:creator>Gurjit Nagra</dc:creator>
                <dc:creator>Mark Wagshul</dc:creator>
                <dc:creator>Shams Rashid</dc:creator>
                <dc:creator>Jie Li</dc:creator>
                <dc:creator>J Pat McAllister</dc:creator>
                <dc:creator>Miles Johnston</dc:creator>
                <dc:source>Cerebrospinal Fluid Research 2010, 7:4</dc:source>
        <dc:date>2010-02-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-8454-7-4</dc:identifier>
        <prism:publicationName>Cerebrospinal Fluid Research</prism:publicationName>
        <prism:issn>1743-8454</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2010-02-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cerebrospinalfluidresearch.com/content/7/1/3">
        <title>Cerebrospinal fluid sodium rhythms</title>
        <description>Background:
Cerebrospinal fluid (CSF) sodium levels have been reported to rise during episodic migraine. Since migraine frequently starts in early morning or late afternoon, we hypothesized that natural sodium chronobiology may predispose susceptible persons when extracellular CSF sodium increases. Since no mammalian brain sodium rhythms are known, we designed a study of healthy humans to test if cation rhythms exist in CSF.
Methods:
Lumbar CSF was collected every ten minutes at 0.1 mL/min for 24 h from six healthy participants. CSF sodium and potassium concentrations were measured by ion chromatography, total protein by fluorescent spectrometry, and osmolarity by freezing point depression. We analyzed cation and protein distributions over the 24 h period and spectral and permutation tests to identify significant rhythms. We applied the False Discovery Rate method to adjust significance levels for multiple tests and Spearman correlations to compare sodium fluctuations with potassium, protein, and osmolarity.
Results:
The distribution of sodium varied much more than potassium, and there were statistically significant rhythms at 12 and 1.65 h periods. Curve fitting to the average time course of the mean sodium of all six subjects revealed the lowest sodium levels at 03.20 h and highest at 08.00 h, a second nadir at 09.50 h and a second peak at 18.10 h. Sodium levels were not correlated with potassium or protein concentration, or with osmolarity.
Conclusion:
These CSF rhythms are the first reports of sodium chronobiology in the human nervous system. The results are consistent with our hypothesis that rising levels of extracellular sodium may contribute to the timing of migraine onset. The physiological importance of sodium in the nervous system suggests that these rhythms may have additional repercussions on ultradian functions.</description>
        <link>http://www.cerebrospinalfluidresearch.com/content/7/1/3</link>
                <dc:creator>Michael Harrington</dc:creator>
                <dc:creator>Ronald Salomon</dc:creator>
                <dc:creator>Janice Pogoda</dc:creator>
                <dc:creator>Elena Oborina</dc:creator>
                <dc:creator>Neil Okey</dc:creator>
                <dc:creator>Benjamin Johnson</dc:creator>
                <dc:creator>Dennis Schmidt</dc:creator>
                <dc:creator>Alfred Fonteh</dc:creator>
                <dc:creator>Nathan Dalleska</dc:creator>
                <dc:source>Cerebrospinal Fluid Research 2010, 7:3</dc:source>
        <dc:date>2010-01-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-8454-7-3</dc:identifier>
        <prism:publicationName>Cerebrospinal Fluid Research</prism:publicationName>
        <prism:issn>1743-8454</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2010-01-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cerebrospinalfluidresearch.com/content/7/1/2">
        <title>Expression and functional activity of nucleoside transporters in human choroid plexus</title>
        <description>Background:
Human equilibrative nucleoside transporters (hENTs) 1-3 and human concentrative nucleoside transporters (hCNTs) 1-3 in the human choroid plexus (hCP) play a role in the homeostasis of adenosine and other naturally occurring nucleosides in the brain; in addition, hENT1, hENT2 and hCNT3 mediate membrane transport of nucleoside reverse transcriptase inhibitors that could be used to treat HIV infection, 3&apos;-azido-3&apos;-deoxythymidine, 2&apos;3&apos;-dideoxycytidine and 2&apos;3&apos;-dideoxyinosine. This study aimed to explore the expression levels and functional activities of hENTs 1-3 and hCNTs 1-3 in human choroid plexus.
Methods:
Freshly-isolated pieces of lateral ventricle hCP, removed for various clinical reasons during neurosurgery, were obtained under Local Ethics Committee approval. Quantification of mRNAs that encoded hENTs and hCNTs was performed by the hydrolysis probes-based reverse transcription real time-polymerase chain reaction (RT-qPCR); for each gene of interest and for 18 S ribosomal RNA, which was an endogenous control, the efficiency of PCR reaction (E) and the quantification cycle (Cq) were calculated. The uptake of [3H]inosine by the choroid plexus pieces was investigated to explore the functional activity of hENTs and hCNTs in the hCP.
Results:
RT-qPCR revealed that the mRNA encoding the intracellularly located transporter hENT3 was the most abundant, with E-Cq value being only about 40 fold less that the E-Cq value for 18 S ribosomal RNA; mRNAs encoding hENT1, hENT2 and hCNT3 were much less abundant than mRNA for the hENT3, while mRNAs encoding hCNT1 and hCNT2 were of very low abundance and not detectable. Uptake of [3H]inosine by the CP samples was linear and consisted of an Na+-dependent component, which was probably mediated by hCNT3, and Na+-independent component, mediated by hENTs. The latter component was not sensitive to inhibition by S-(4-nitrobenzyl)-6-thioinosine (NBMPR), when used at a concentration of 0.5 &#956;M, a finding that excluded the involvement of hENT1, but it was very substantially inhibited by 10 &#956;M NBMPR, a finding that suggested the involvement of hENT2 in uptake.
Conclusion:
Transcripts for hENT1-3 and hCNT3 were detected in human CP; mRNA for hENT3, an intracellularly located nucleoside transporter, was the most abundant. Human CP took up radiolabelled inosine by both concentrative and equilibrative processes. Concentrative uptake was probably mediated by hCNT3; the equilibrative uptake was mediated only by hENT2. The hENT1 transport activity was absent, which could suggest either that this protein was absent in the CP cells or that it was confined to the basolateral side of the CP epithelium.</description>
        <link>http://www.cerebrospinalfluidresearch.com/content/7/1/2</link>
                <dc:creator>Zoran Redzic</dc:creator>
                <dc:creator>Slava Malatiali</dc:creator>
                <dc:creator>Danica Grujicic</dc:creator>
                <dc:creator>Aleksandra Isakovic</dc:creator>
                <dc:source>Cerebrospinal Fluid Research 2010, 7:2</dc:source>
        <dc:date>2010-01-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-8454-7-2</dc:identifier>
        <prism:publicationName>Cerebrospinal Fluid Research</prism:publicationName>
        <prism:issn>1743-8454</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2010-01-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cerebrospinalfluidresearch.com/content/7/1/1">
        <title>The regulation of brain states by neuroactive substances distributed via the cerebrospinal fluid; a review </title>
        <description>The cerebrospinal fluid (CSF) system provides nutrients to and removes waste products from the brain. Recent findings suggest, however, that in addition, the CSF contains message molecules in the form of actively released neuroactive substances. The concentrations of these vary between locations, suggesting they are important for the changes in brain activity that underlie different brain states, and induce different sensory input and behavioral output relationships.The cranial CSF displays a rapid caudally-directed ventricular flow followed by a slower rostrally-directed subarachnoid flow (mainly towards the cribriform plate and from there into the nasal lymphatics). Thus, many brain areas are exposed to and can be influenced by substances contained in the CSF. In this review we discuss the production and flow of the CSF, including the mechanisms involved in the regulation of its composition. In addition, the available evidence for the release of neuropeptides and other neuroactive substances into the CSF is reviewed, with particular attention to the selective effects of these on distant downstream receptive brain areas. As a conclusion we suggest that (1) the flowing CSF is involved in more than just nutrient and waste control, but is also used as a broadcasting system consisting of coordinated messages to a variety of nearby and distant brain areas; (2) this special form of volume transmission underlies changes in behavioral states.</description>
        <link>http://www.cerebrospinalfluidresearch.com/content/7/1/1</link>
                <dc:creator>Jan Veening</dc:creator>
                <dc:creator>Henk Barendregt</dc:creator>
                <dc:source>Cerebrospinal Fluid Research 2010, 7:1</dc:source>
        <dc:date>2010-01-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-8454-7-1</dc:identifier>
        <prism:publicationName>Cerebrospinal Fluid Research</prism:publicationName>
        <prism:issn>1743-8454</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2010-01-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
